Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jan 24;8:14. doi: 10.1186/s13287-016-0465-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2017

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 5 — Immunosuppressive properties of CB-MSC. a-b Inhibitory effect of resting (a) and primed (b) LL-CBMSC on allogeneic CFSE-labeled PBMC. Cells were co-cultured at different PBMC:MSC ratios upon PBMC stimulation with anti-CD3 and rh-IL-2 for 6 days. Three different PBMC:MSC ratios were used ranging from 1:0.2 to 1:0.05. The 1:0 ratio represents the positive control (no MSC treatment and presence of PBMC antibody stimulation). Proliferation was assessed by CFSE dilution method on CD45+ cells. Each bar represents mean and SEM of two independent experiments with two different PBMC donors for each of four CB-MSC batches. c Proliferation ratio between the percentage of CD45+ proliferation at primed and resting conditions, at the different MSC doses. The differences were computed by two-way ANOVA, ^** p < 0.01, ^*** p < 0.001